Carroll Financial Associates’s Kalaris Therapeutics KLRS Stock Holding History

Carroll Financial Associates’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$13K	Buy	+43	New	+$19.9K	﹤0.01%	1102

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Carroll Financial Associates's KLRS Position: Q4 2021 in Review

Carroll Financial Associates opened a new position in Kalaris Therapeutics (KLRS) in Q4 2021: 43 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #1102 among its holdings.

84 funds tracked by Wall St. Rank hold KLRS as of Q4 2021.

Carroll Financial Associates held 43 shares of Kalaris Therapeutics worth $13K as of Q4 2021.
Kalaris Therapeutics was a new Carroll Financial Associates position in Q4 2021.
Kalaris Therapeutics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1102 holding.
84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.